CORSA study finds spike-specific blunted immune responses in lymphoma patients after SARS-CoV-2 vaccine
By
Lucia Mazzotti
Gerardo Musuraca
Fabio Affaticati
Esther Bartholomeus
Diana Campillo-Davo
Carole Faghel
Chiara Zingaretti
Flavia Foca
Claudio Cerchione
Valentina Ancarani
Patricia Borges de Souza
Fabio Nicolini
Anna De Lucia
Anna Gaimari
Oriana Nanni
Vittorio Sambri
Giovanni Martinelli
Francesco Malaspina
Pieter Meysman
Eva Lion
Massimiliano Mazza
May 20, 2026
Clinical Scorecard: CORSA trial reveals diminished immune responses to SARS-CoV-2 vaccination in lymphoma patients with spike-specificity
At a Glance
Category Detail
Condition Lymphoma patients receiving treatment Key Mechanisms Impaired immune function due to disease and therapy, particularly from treatments like Rituximab Target Population Patients with hematological malignancies undergoing active treatment Care Setting Oncology and immunology clinics
Key Highlights
Only 8% and 21% of lymphoma patients seroconverted after the first and second vaccine doses, respectively. 69% of seronegative lymphoma patients exhibited measurable T-cell activity post-vaccination. Lymphoma patients showed significantly weaker Spike-specific clonal responses compared to healthy controls. Guideline-Based Recommendations
Diagnosis
Assess immune responses in lymphoma patients post-vaccination using serological and T-cell activity tests. Management
Consider alternative protective strategies for lymphoma patients due to diminished vaccine responses. Monitoring & Follow-up
Regularly monitor T-cell responses and antibody levels in lymphoma patients receiving COVID-19 vaccinations. Risks
Increased risk of severe COVID-19 outcomes in lymphoma patients, including higher hospitalization and mortality rates. Patient & Prescribing Data
Patients with hematological malignancies, particularly those treated with immunosuppressive therapies.
Immunosuppressive treatments like Rituximab significantly reduce vaccine-induced immune responses.
Clinical Best Practices
Prioritize vaccination in lymphoma patients while considering their unique immune response challenges. Utilize a combination of serological and cellular response assessments to evaluate vaccine efficacy. Related Resources & Content
